Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.63%, the Hang Seng Tech Index down by 0.67%, and the Hang Seng China Enterprises Index decreasing by 0.88% [1] - In contrast, the innovative drug sector saw significant gains, with the Hang Seng Biotechnology Index rising by 2.97% [1] Company Performance - Xiaomi Group's stock dropped over 3%, with a maximum intraday decline exceeding 5% [2][3] - Innovative drug stocks performed well, with Huahao Zhongtian Pharmaceutical surging over 55%, Kangfang Biotech increasing by 14.33%, and other companies like Basestone Pharmaceuticals and Innovent Biologics also showing positive growth [6] IPO Activity - Luxshare Precision announced plans to issue H shares and list on the Hong Kong Stock Exchange [7] - Lens Technology has initiated its IPO process, planning to officially list on July 9 [8] - GoerTek intends to spin off its microelectronics subsidiary for an IPO in Hong Kong [9] - These companies are recognized as the "three giants of the fruit chain," and the China Securities Regulatory Commission has expressed support for leading domestic enterprises to list in Hong Kong [10] Regulatory Developments - The Hong Kong Stock Exchange launched an Integrated Fund Platform (IFP) order transmission service to enhance market efficiency [11] - The service aims to connect key participants in the fund distribution ecosystem and will welcome 33 companies as initial participants [12]

Company Overview - Tian Gong Co., Ltd. is recognized as a national-level specialized and innovative "little giant" in the titanium alloy sector, primarily engaged in the research, production, and sales of titanium and titanium alloy materials [1][2] - The company processes titanium sponge into various titanium products, including titanium plates, pipes, ingots, and rods, which are widely used in high-tech industries such as consumer electronics, aerospace, marine engineering, chemical energy, biomedical, and 3D printing [1][2] Business Performance - The company has established a deep partnership with Changzhou Soloman, a key player in Apple's supply chain, leading to significant revenue growth [2] - In 2024, sales to Soloman and its affiliates are projected to reach 575 million yuan, a fivefold increase from 2022, with revenue contribution rising from 27.88% to 71.72% [2] - The company is also expanding its product offerings in aerospace and medical applications, having obtained relevant certifications and achieving breakthroughs in high-end applications [2] Industry Insights - The titanium processing industry in China has shown stable growth, with production increasing from 48,600 tons in 2015 to 159,100 tons in 2023, representing a compound annual growth rate (CAGR) of 15.97% [3] - Sales volume in the same period grew from 43,700 tons to 148,400 tons, with a CAGR of 16.51% [3] Financial Performance - The company reported revenues of 383 million yuan, 1.035 billion yuan, and 801 million yuan for the years 2022, 2023, and 2024, with year-on-year growth rates of 35.65%, 170.05%, and -22.59% respectively [3] - Net profit attributable to shareholders was 70 million yuan, 170 million yuan, and 172 million yuan for the same years, with growth rates of 244.00%, 142.57%, and 1.57% respectively [3] IPO and Strategic Investors - Tian Gong Co., Ltd. plans to issue 69 million shares, raising 272 million yuan, with the funds allocated for a project to build a production line for 3,000 tons of high-end titanium and titanium alloy rods and wires [3] - The company has attracted a prestigious group of 12 strategic investors, with 30% of the shares allocated for strategic placement, indicating strong institutional confidence [4] Market Sentiment and Valuation - The company is expected to perform well on its first trading day, with potential price increases based on recent trends in new stock listings [5][6] - The dynamic price-to-earnings ratio at the time of issuance is 14.8 times, significantly lower than the average of 51 times for comparable companies, suggesting a strong valuation advantage [6][7] - The initial offering price of 3.94 yuan is relatively low compared to recent new listings, which may lead to speculative trading [7][8]

Core Viewpoint - The company Aiai Precision (艾艾精工) is set to resume trading on April 30, following its cash acquisition of Taizhou Zhongshixin, which is expected to enhance its revenue and profit through diversification into the supply chain for consumer electronics components [1][4]. Financial Performance - In 2024, Aiai Precision reported a revenue of 168 million yuan, an increase of 8.35%, but a net profit of -3.99 million yuan due to non-recurring losses [2]. - The company aims to improve its financial situation in 2025, focusing on enhancing its core business revenue and profitability [2]. - In Q1 2025, Aiai Precision achieved a revenue of 47.64 million yuan, a year-on-year increase of 30.18%, and a net profit of 5.41 million yuan, reflecting a significant growth of 338.97% [2]. Acquisition Details - Aiai Precision plans to acquire 50.2008% of Taizhou Zhongshixin for a total of 125 million yuan, gaining control over the company [3]. - Taizhou Zhongshixin specializes in the research, production, and sales of precision metal structural components and has recently entered the supply chain for fruit chain customers [3][4]. - The acquisition is expected to allow Aiai Precision to enter the consumer electronics parts market, diversifying its business and enhancing its sustainable development capabilities [4]. Future Commitments - The sellers of Taizhou Zhongshixin have committed to achieving net profits of no less than 18 million yuan, 25 million yuan, and 37 million yuan for the years 2025, 2026, and 2027, respectively, totaling at least 80 million yuan [4].